NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to Paris<
09 Oct 2023

CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to Paris

The company occupies over 2,400m² of production, laboratory, and office space.
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments<
03 Oct 2023

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & Development, Mark Plavsic, Ph.D., Appointed as Chief Technology Officer
Palex and Inbiomotion introduce pioneering test to aid oncologists in predicting recurrence and survival rates in breast cancer patients<
28 Sep 2023

Palex and Inbiomotion introduce pioneering test to aid oncologists in predicting recurrence and survival rates in breast cancer patients

Spain is the first country in the world to have this technology
SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics<
26 Sep 2023

SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics

Milestone broadens partnership to develop novel ocular therapies using CRISPR-based technologies

CorWave announces the appointment of Magalie Durrèche as Chief Financial Officer<
26 Sep 2023

CorWave announces the appointment of Magalie Durrèche as Chief Financial Officer

Magalie Durrèche has over twenty years of experience in corporate finance, mainly in the industrial sector
Am-Pharma announces updated clinical development strategy<
26 Sep 2023

Am-Pharma announces updated clinical development strategy

Advancing ilofotase alfa into a Phase 2 study for lead indication cardiac surgery-associated renal damage
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas<
14 Sep 2023

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

Announced the appointments of Daphne Karydas and Glenn Sblendorio to its Board of Directors
Xeltis appoints Luciën van Os as Chief Operating Officer<
12 Sep 2023

Xeltis appoints Luciën van Os as Chief Operating Officer

Luciën joins Xeltis with more than 20 years of experience in the life sciences sector
Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension<
10 Sep 2023

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

Robust trial design and results led to lorundrostat being first of new class, aldosterone synthase inhibitors, to start pivotal clinical program in hypertension
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions<
10 Sep 2023

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.